| 000 | 01108 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250512091921.0 | ||
| 264 | 0 | _c19730924 | |
| 008 | 197309s 0 0 eng d | ||
| 022 | _a0022-3573 | ||
| 024 | 7 |
_a10.1111/j.2042-7158.1973.tb10642.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShulgin, A T | |
| 245 | 0 | 0 |
_aStereospecific requirements for hallucinogenesis. _h[electronic resource] |
| 260 |
_bThe Journal of pharmacy and pharmacology _cMar 1973 |
||
| 300 |
_a271-2 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aDOM 2,5-Dimethoxy-4-Methylamphetamine _xpharmacology |
| 650 | 0 | 4 |
_aAmphetamine _xpharmacology |
| 650 | 0 | 4 | _aCircular Dichroism |
| 650 | 0 | 4 |
_aHallucinogens _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMolecular Conformation |
| 650 | 0 | 4 | _aOptical Rotation |
| 650 | 0 | 4 | _aStereoisomerism |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 773 | 0 |
_tThe Journal of pharmacy and pharmacology _gvol. 25 _gno. 3 _gp. 271-2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.2042-7158.1973.tb10642.x _zAvailable from publisher's website |
| 999 |
_c4151840 _d4151840 |
||